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S. E. A. Eley, A. G. McKechanie, S. Campbell & A. C. Stanfield
Patrick Wild Centre, Division of Psychiatry, University of Edinburgh, Edinburgh, UK
Abstract
Background Recently, there has been an increasing
number of trials of medications for fragile X
syndrome (FXS). In order to be adequately powered,
trials have involved many centres around the world
with relatively small numbers of participants recruited
at each site. This study aims to understand the
barriers to, and how best to facilitate participation in,
medication trials in order to improve recruitment and
the experience of participants with FXS.
Methods A mixed methods design was used to
collect both quantitative and qualitative data.
Participants were invited to participate through the
UK Fragile X Society, a local mailing list and through
social media. Those who agreed to participate
completed a quantitative questionnaire and indicated
whether they would be willing to participate in a
follow‐up focus group.
Results The questionnaire was completed by 328
individuals who either had FXS, or were a parent,
carer or family member of an individual with FXS.
Over two‐thirds of participants reported concern
about side effects, while over one‐third mentioned
swallowing tablets, blood tests, financial aspects and
travel as barriers to participation. Focus groups with
12 individuals highlighted themes of trial challenges,
strategies to overcome these and motivating factors to
participate.
Conclusions Many of the factors, which potentially
negatively influence participation in a clinical trial for
FXS, could be mitigated in relatively simple ways.
Easily accessible information, particularly about
safety issues, the research team and the trial
environment should be standard practice.
Desensitisation programmes for blood testing,
provision of different preparations of medication (e.g.
liquid) and use of a combination of local, remote and
site visits to reduce travel and time should also be
considered.
Keywords clinical trials, fragile X syndrome,
participation, recruitment
Background
Fragile X syndrome (FXS) is the most common
known inherited form of intellectual disability (ID)
with a prevalence of 1.4 per 10 000 male and 0.9 per
10 000 female patients (Hunter et al., 2014). The
physical presentation of the condition is well
described, although the exact features may vary
considerably between patients. (Hagerman and
Hagerman, 2002; Kidd et al., 2014). ID in people
with FXS can vary from mild to severe; however, it is
most commonly within the moderate range, with male
patients often more affected than female patients. In
addition to the characteristic physical features and ID,
individuals with FXS also commonly present with a
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number of behavioural features, which include
hyperactivity, anxiety and autistic traits (Tsiouris and
Brown, 2004).
As with other forms of ID, the management of FXS
is multidisciplinary in nature. Medication can have a
role to play for some individuals, but at present, the
medical treatments used are primarily symptomatic in
nature. These include the use of selective serotonin
reuptake inhibitors for anxiety, stimulants for
attention deficit hyperactivity disorder and
antipsychotics for irritability or aggressive behaviour
(Tsiouris and Brown, 2004). In recent years, there
has, however, been an increase in the number of
medications suggested to target the underlying
neurobiology of FXS, and subsequently, a number of
these have been brought to clinical trial (Krueger and
Bear, 2011; Lee et al., 2018).
Participation in clinical research by people with ID
is known to be associated with particular difficulties,
such as identifying and recruiting appropriate
participants, obtaining informed consent and
difficulties associated with study procedures (Oliver‐
Africano et al., 2010). These difficulties are likely to
be amplified for clinical treatment trial participation,
as individuals are often required to attend trial sites on
multiple occasions and undergo invasive procedures,
such as blood sampling. It is notable that the largest
clinical trials that have occurred in FXS have required
multinational efforts to recruit a relatively small
number of participants (Berry‐Kravis et al., 2016;
Hagerman et al., 2018; Youssef et al., 2018). Not only
are such trials complex to manage and expensive to
run, they also introduce risks to trial fidelity, in
particular intersite variability in clinical assessments.
There is therefore a need to understand the factors
that affect participation in clinical trials of
medications for FXS, to increase the feasibility of
conducting future trials. A number of previous
studies have used either survey‐based or qualitative
interview‐based methods to examine parental
attitudes towards pharmacological trials in FXS
(Chechi et al., 2014; Reines et al., 2017; Richstein
et al., 2017; D’Amanda et al., 2019). These have
suggested that concerns about medicating children,
issues around consent, logistical burdens and invasive
trial procedures are seen as barriers to participation,
whereas altruistic motives and therapeutic optimism
are potential motivating factors. While informative, a
potential limitation of these studies is that they have
occurred in relatively small groups of people and/or
have been recruited through single specialist centres
and so may not be representative of the broader
population of people with fragile X and their families.
We therefore set out to investigate the barriers to
participation in drug trials and how these could be
overcome in a large population of families affected by
FXS recruited from diverse sources.
Methods
Data collection
A mixed methods design was used, collecting both
quantitative and qualitative data. A quantitative
questionnaire was completed by parents, carers,
family members of individuals with FXS or by people
with FXS themselves. Carers were permitted to assist
those with FXS to complete the questionnaire. The
questionnaire contained seven questions (Supporting
Information). These examined any previous
involvement with clinical trials, willingness to
consider taking part in future clinical trials, potential
barriers to trial participation (with 11 possible
2
FIGURE 1. Proportion of all respondents endorsing each item as a
potential barrier to clinical trial participation. [Colour figure can be
viewed at wileyonlinelibrary.com]
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responses – Fig. 1), concerns regarding medical trials
and what could be done to encourage participation.
At the end of the survey, participants indicated if
they were willing to take part in a follow‐up focus
group. Those who consented were then invited to one
of three focus groups, located around the United
Kingdom. For the focus groups, a number of prompts
were developed around which the discussion was
framed. Specifically, they were asked about their
current understanding of clinical trials and what they
would want to know before deciding whether or not
to take part in a trial. They were also asked to imagine
they were designing a clinical trial and what they
would take into consideration.
Recruitment
Recruitment proceeded through three sources.
Firstly, paper copies of the questionnaire were sent to
over 1000 families through the UK Fragile X Society,
the main support organisation for families with FXS
in the United Kingdom. In addition, an email with a
link to an online questionnaire was sent to individuals
registered with The Patrick Wild Centre research
centre at the University of Edinburgh. Finally, a link
to the online version of the questionnaire was adver-
tised on the research centre website, Facebook page
and Twitter feed.
In order to participate, all individuals had to be over
the age of 18 and either be a family member or a carer
of someone with a diagnosis of FXS or have FXS
themselves.
Ethical approval for the study was granted by the
Accord Medical Research Ethics Committee at the
University of Edinburgh. Consent for the
questionnaire was implied through its completion;
written informed consent was collected from
individuals who took part in the focus groups.
Quantitative analysis
The analysis for the questionnaire data was
conducted using IBM Statistical Package for Social
Science (SPSS) (IBM SPSS Statistics for Windows,
Version 22.0. Armonk, NY: IBMCorp). The primary
results were considered using descriptive statistics.
Chi‐squared tests were used to determine whether or
not an expressed interest in taking part in clinical
trials made a difference to the barriers reported.
Qualitative analysis
The focus group data were analysed using a thematic
analysis approach (Braun and Clarke, 2006).
Following completion of all focus groups, the audio
recordings were transcribed. Initial codes were
generated from the data, and these were sorted into
draft thematic groups. These draft thematic groups
were then reviewed and refined after considering the
validity of each theme in relation to the whole data set
until final themes were generated and a thematic map
was developed. This process was conducted by both
the researcher who facilitated the groups (SE) and a
researcher external to the study team (SH). NVIVO
software (QSR International Pty Ltd. Version 10,




A total of 328 people completed the questionnaire;
94.5% were parents of individuals with FXS, 3.3%
were carers and 2.2% had a diagnosis of FXS.
Nineteen per cent of people had previously taken part
in a drug treatment trial of new medicines. Of the
people who had taken part in a previous trial, 61% had
a positive experience, 33% reported having a mixed
experience and 3% had a negative experience.
Out of all the participants, 45.7% stated they would
consider participating in future clinical trials, 42.5%
would maybe consider participating and 11.8% would
not consider it. Those who had previously
participated in trials were significantly more likely
(P ¼ 0.02) to take part in a future trial, with 62% of
those who have previously taken part expressing they
would consider participating in a future trial,
compared with 40% of those who had not previously
taken part.
Figure 1 summarises the barriers to participation
highlighted through the questionnaire. The most
commonly reported barrier was concern over side
effects, which was endorsed by over two‐thirds of
participants, while over one‐third of participants
reported potential difficulties with trial procedures
(swallowing tablets and blood tests) or practicalities
(financial aspects and travel) as barriers to
participation. Of those who endorsed the ‘other’
category, novel responses that were not covered
3
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elsewhere in the questionnaire included concern
about seeing benefits from a trial then having to stop
the medication, difficulties participating due to their
child not living with them and not being made aware
of trials.
Table 1 shows the barriers identified by participants
and compares the barriers identified in those who
would be willing to participate in a future trial and
those who would not. For six of the barriers, there was
a significant difference (P < 0.05) between those who
reported that they would or would not consider taking
part in a clinical trial.
Those who said they would not participate in future
trials more frequently reported the following as
barriers to participation: taking a new medicine,
taking an existing medicine that was not yet licensed
in FXS, having to undergo blood tests and visiting a
new place and the risk of side effects. Those who said
they would or maybe would participate in future trials
more frequently reported travel as a barrier.
Qualitative findings
A total of 182 people who completed the
questionnaire indicated willingness to be part of a
focus group. The focus groups took part in three
locations throughout the United Kingdom to ensure
as many people could take part as possible. A total of
52 invitations were sent, with 12 individuals agreeing
to participate. Of the people who took part, 11 were
parents, 1 was a carer of an individual with FXS and
none of the participants had FXS themselves.
Data from the transcribed interviews were initially
split into 115 codes, which were then split into six
categories and then grouped into themes, each with
several subthemes. The three major themes that
emerged from the data were trial challenges/barriers,
strategies to assist participation and motivating
factors. The main themes and subthemes identified
following the coding are shown in a thematic map in
Fig. 2. Each of the three themes are discussed in turn
below.
Theme 1: Trial challenges/barriers
Travel. Travel was primarily seen as being an issue
due to the time it would take and the interruption to
the trial participant’s routine. This was particularly
reported to be the case if several research
appointments were required:
It would have to be localI don’t have time to travel
… My boy loves travelling but we just can’t afford
the timeIt was mentioned in several of the focus
groups that being given the option to travel together
in a group would help to relieve some of the
anxieties regarding potential travel issues:
Travelling with Fragile X is not, oh it’s a joy
(laughter)It would be friendly … it would be an
anxious situation but if you knew you were going to
fly together and meet at the airport …It was also
mentioned that if the travel could be arranged for
them so they did not have to organise it themselves,
this would be helpful:
it’s all taken care of so you don’t have to worry
about it”
Procedure‐related difficulties. There were many
concerns raised around the participant’s ability to
have their blood taken, being able to take medication
and to cope with other trial procedures. Many parents
4
Table 1 Proportion of individuals, divided by willingness to
participate in future trials, reporting which items would be a barrier
to participation (significant differences highlighted in bold).









New medicine 13.3 48.6 33.1 25.42<0.001
Existing unlicensed
medicine
7.0 40.5 22.6 26.81<0.001
Blood tests 26.6 40.5 39.8 6.26 0.04
Travel 43.4 32.4 54.9 7.24 0.03
Unknown research team 17.5 27.0 24.8 2.87 0.24
New place 16.1 27.0 29.3 7.20 0.03
Swallowing medication 30.1 29.7 39.1 2.83 0.24
Time 23.8 35.1 33.1 3.64 0.16
Financial 31.5 21.6 39.8 4.97 0.08
Side effects 55.9 81.1 69.2 10.29 0.006
For example, 13.3% of those people who were willing to participate in a
future trial endorsed concern about taking a new medication as a
significant barrier to participation, whereas this concern was endorsed by
48.6% of those who indicated they were unwilling to participate in a future
trial.
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talked about previous experiences trying to give their
child medications in different forms and discussed the
need for researchers to have options available:
My daughter will not and cannot take any
medication in the form of tabletsTaking blood
came up as a barrier in all three focus groups and
was repeatedly brought up on different occasions
throughout each group:
I nearly had my fingers broken while [child] has
been having their blood takenHowever, parents
recognised the importance of bloods for safety
reasons and would not want this compromised.
They expressed the wish for education about why
the blood test was required and whether each one
was a core part of the trial or an optional add‐on (as
has been the case in some trials):
They are important so I am not sure they could be
reduced in a trialI think they need to tell you why
they do the blood tests then you would know
Side effects/safety. The focus groups confirmed that
potential side effects and toxicity of a new medication
is of primary concern:
Safety is number oneI am very, very wary of the
toxicityOne participant commented on the issues
they had had in previous trials that have had a
knock‐on impact on future participation. The
participant focused on their child’s inability to
verbally express the issues and side‐effects she was
experiencing:
[child] Non‐verbal … so when you’re talking about
drug trials… [child] would cry and you wouldn’t
know whyThe overall concerns of taking new
medications, which may have unpredictable side
effects, were effectively summarised by one
participant who stated that
I think a lot of people want to help but then they
just don’t know how their child is going to react
Environment. The environment relates to where the
trial should take place. There were some participants
that would favour the trial being done in their own
home as it would mean they did not have to travel and
would take up less time. They also felt their child may
be more relaxed.
I think it would have to be local familiar
territoryBased at home would be niceHowever,
5
FIGURE 2. Themes and subthemes identified through the thematic analysis.
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other participants felt it would be better to go
somewhere else outside their home in case there
were any negative consequences associated with the
trial that they did not want to be associated with
home:
I don’t want home being associated with blood tests
Consent. As the majority of people attending the focus
groups were parents to a child with FXS, one of the
main concerns was over them consenting on behalf of
their child.
Saying yes for someone else is a big
responsibilityDo whatever you want to me but my
child is differentWhile the parents understood that
legally they were able to consent on behalf of their
child, they were concerned that their child would
not be able to understand why they would be taking
part.
I don’t think he would really understand why we
were doing it so that’s not informed consent is it?I
don’t think he would understand what I was trying
to explain to him
Theme 2: Strategies to assist participation
The main subthemes that came out were information
giving, environment, preparation, support, flexibility
and time.
Information giving. The focus groups made it very
clear that they wanted as much information on the
trial medication as possible, and having this
information would help alleviate anxieties about side
effects and safety. They also reported wanting easily
understandable information broken into small
sections. It was suggested to have a short and long
information sheet, so if someone was interested, they
could access more detailed information. The
participants felt if they had sufficient information
about the trial medication and were made aware of
previous safety trials and potential side effects, then
they could weigh these up and would be more likely to
participate:
… sign up for it straight away if something had
already gone through safety trialsI’d have more
worries about a completely new drug than one
that’s already been used and obviously the side
effects were known
Many people reported wanting to meet the research
team and have the opportunity to ask questions in an
informal environment with the chance to listen to
other people’s questions. They also felt this was impor-
tant to build a trusting relationship with researchers.
It was also reported that families did not necessarily
feel they could contact the researcher to discuss the
trial in more detail, despite adverts and information
sheets explicitly inviting this. They reported that if
they were to see something negative in the
information sheet, this could lead them to dismiss the
trial without further consideration, rather than
contacting the research team. Information events
would help to reduce this risk by giving families the
chance to discuss concerns in more detail in a neutral
environment:
I think families want to meet you and talk
Environment. While environment was discussed
under barriers to participation, it was also felt that this
could assist participation in clinical trials through
enabling people with FXS to become comfortable in
clinical environments, which would be especially
useful if they were local:
Local hospitals, local clinicians … local clinicians
getting to know them, actually that would be good
for us
Preparation. Before taking part in a clinical trial,
many of the participants mentioned the importance of
preparing their child to help them understand what
they were going to be doing and why. It was discussed
that if the trial team could provide easy to understand
information, they could share with their child that
would be very beneficial:
A story board of what is going to happenIt was also
highlighted that if their child was well prepared for
blood tests, then this would be beneficial and make
future routine tests at the doctors much easier:
6
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Education packs for kids so that they understand
the process of taking bloodWin: you get the blood
sample, we get a kid that is probably going to be
able to give blood in the future
Support. In each group, there was a positive
discussion towards participating in research studies
at the same time as other families to gain social
support and have contact with families in a similar
situation to themselves.
you could make friends locallyIt was mentioned
that travelling with others would not only take away
the stress but would also be a good opportunity to
get social support from other families:
With other families, they understand so I can just
relax a bit
Flexibility. Flexibility of the trial was mentioned
frequently. Participants discussed in particular the
barrier of their child’s ability to take medication and
that flexibility around preparation (e.g. if the trial
drug could be given via a patch, liquid or suppository)
would make a big difference to whether or not their
child could take part:
If it’s drugs, personalise the method of
administrationIt was also suggested that being
flexible with trial visit location would be helpful,
especially if the primary site was some distance
from their home:
You need a combination don’t you? You need
something you do locally … then maybe a biannual
trip further afieldAlso, being flexible with regards to
the testing required could make a difference, for
example taking blood in a different way such as
using a finger prick sample or if possible take
samples less often:
Find a different way to get bloods that would be
good
Time. Related to the above, it is important to take
into account the distance to be travelled when
designing the visit schedule. Families reported being
prepared to travel to a research appointment every few
weeks if the appointment was nearby but most would
not manage this frequency if it was further away and
required more time:
Within an hour’s travel might work
Theme 3: Motivating factors
There were many different motivating factors for
parents/carers wanting their dependant to take part in
clinical trials; however, the same reasons were echoed
in every focus group: therapeutic optimism and
altruism. Importantly, many did not want their child
to fundamentally change but rather to see
improvements in certain areas of their lives such as
anxiety, learning and concentration:
the biggest thing for my son is anxietyanxiety and
concentrationThey wanted their child to be able to
achieve more, not necessarily in terms of their
cognitive abilities, but rather to be able to go into
social situations or crowded places without feeling
uncomfortable, thus allowing them to live a fuller
life:
Anything that helps my daughter to be able to say
her own name … anything that helps her achieve a
bit more in lifeFinally, the importance that clinical
trials take place to further understand FXS and to
help the next generation was echoed in each focus
group:
Trials have to be looked at as positiveIf we didn’t
try things we wouldn’t get anywhere would we?
Discussion
In this study, we set out to expand upon the current
literature by using a mixed methods approach to
examine barriers to clinical trial participation in FXS
and how they might be overcome. We found that
concern over potential side effects was the most
commonly reported factor to potentially negatively
affect participation in clinical trials. Concerns over the
study procedures and the effects of the study on wider
life were also important potential barriers to
7
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participation. Further exploration during the focus
groups highlighted that these barriers had significant
complexities to them and revealed potential strategies
by which they may be overcome.
While the current study collected data only on
individuals with FXS, it is possible, indeed likely,
that at least some of our findings could be extended
to other groups of people with ID. Given the notably
high rates of autism in FXS it may be that certain
aspects, such as difficulty coping with a new
environment or research team, would be more
common than in other forms of ID. However, we
would anticipate that other concerns around safety
and trial procedures would be generalisable beyond
FXS. Future research should compare findings
between different syndromes, non‐syndromic ID and
idiopathic ID to identify both syndrome specific
factors and those which are applicable more broadly.
Study procedures
Concern about potential side effects was the most
frequently reported barrier, which is consistent with
previous literature, both in FXS (Chechi et al., 2014;
Reines et al., 2017; D’Amanda et al., 2019) and more
generally (Ross et al., 1999; Oliver‐Africano
et al., 2010; Chechi et al., 2014), where side effects
have been reported to be one of the largest barriers to
participation in clinical trials. The focus groups
reported that this concern was particularly pertinent
in FXS due to the presence of communication
difficulties, that is families were concerned that their
child may have difficulty reporting side effects and
that these may then be expressed as distress or
difficult behaviour.
Interestingly, the focus groups revealed that
families do not expect drug trials to be risk free;
however, they were very keen to receive as much
information as possible so that they can make a fully
informed decision. Providing such information in an
open and transparent manner may therefore go some
way towards diminishing their concerns.
From the quantitative questionnaire, the need for
blood tests was frequently highlighted as a barrier to
trial participation. However, when blood tests were
discussed in the focus groups, families recognised the
importance of safety bloods and understood their
necessity. It was proposed that a good way to
overcome concern about phlebotomy would be to
provide education packs in advance to prepare the
participant with FXS. In addition, the possibility of
using the trial as an opportunity to do desensitisation
work around blood‐taking was raised as a potentially
positive aspect of participating, and that for some, it
may be a motivator.
Taking part in a clinical trial with an unknown
research team in an unfamiliar environment was
highlighted by around a fifth of those who completed
the questionnaire. This rate was consistent regardless
of whether they stated they would or would not like
to take part in a future trial (Table 1), suggesting that
this factor may not have a strong impact as to
whether someone chooses to take part or not. In
focus groups, families discussed that it would be
preferable for the affected individual to meet the
research team beforehand to help ease anxiety.
Ideally, research could be conducted by local
clinicians so the individual with FXS could build up
a relationship with these clinical teams.
Swallowing medication was reported as a barrier by
35% of participants. The same percentage of people
reported this as a barrier regardless of whether or not
they would choose to take part in a future clinical trial.
In focus groups, different methods of medication
administration were discussed, and it was clear that
flexibility in administration methods would maximise
participation.
Interestingly, potential randomisation to a placebo
arm was not described as a barrier to participation in
this study. This was somewhat surprising given that
previous research has suggested that this may be a
factor in trial participation for other conditions
(Welton et al., 1999; Bardakjian et al., 2019) and that
recruitment may be easier when participants are
informed what they are taking (Treweek et al., 2018).
Our lack of findings in this area may relate to
methodological issues, specifically that we did not
include this as a suggested barrier in our
questionnaire. It should be noted however that the
issue of placebos was raised during the focus groups
but was not considered by participants to have any
effect on their willingness to participate, suggesting
that the potential for being randomised to the
placebo arm is not a significant barrier to
participation in this group.
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Effects of study on wider life
The second most commonly reported barrier to
participation was travel (49%). From the focus group
discussions, it was clear that these concerns were not
simply about the mode of transport and associated
anxiety but also included the time involved, the
frequency of appointments and possible interruption
to routine. People reported that it was reasonable to
travel short distances on a regular basis and would be
willing to travel further for more infrequent visits. It
was also suggested in a questionnaire response that
visits conducted remotely would make participation
easier and encourage others to take part in new trials.
Many were open to the idea of travelling with their
child, particularly if they could do this with other
families who could provide peer support. It is
interesting to note that despite travel being reported
as one of the main barriers to participation, 44% of
people who cited this as a potential barrier would still
consider taking part in a clinical trial.
Financial impacts were also reported as potentially
important barriers to participation. The results from
the focus groups showed that some families were
unaware that all travel and subsistence would be
covered, indicating the importance of providing early
reassurance about this. It should be noted that
financial concerns also extended to indirect factors,
not commonly covered in trial budgets, such as taking
time off work.
Overcoming barriers
In addition to the ways of overcoming specific barriers
discussed above, one factor that came up repeatedly
in each focus group was the importance of having
accessible information to help families to understand
the study. Particularly, having information on any
potential safety issues and having it presented in a
variety of easy‐to‐understand formats were felt to be
important ways to facilitate participation. The
respondents felt that a good way to get information on
the study would be to meet the research team at
information evenings and to have an opportunity to
ask questions in an informal setting. This was felt to
be less daunting than directly contacting a researcher
in response to an invitation to take part. The families
suggested that if questions could be asked at an early
stage then this would help to reduce anxieties and
promote trust, meaning that they would be more
likely to find a way to overcome perceived barriers in
order to take part in a study.
Limitations
Despite people from 13 countries across 5 continents
completing the study, the results are still limited by a
relatively small sample size. It should also be
highlighted that participants in the study are
potentially biased towards those already interested in
research and to those who are actively engaged with
FXS communities in the United Kingdom and on-
line. Thus, these results must be seen in the context of
barriers to research for those who are at least already
contemplative of participation in research. Potential
barriers were suggested in the questionnaire and,
therefore, may have influenced the responses given; in
particular, we did not include inclusion in the placebo
arm as one of the specific barriers suggested, which
may explain why this was not considered to be an is-
sue by focus groups. However, the focus groups were
carried out over 6 months after the questionnaire was
completed, which likely reduced the risk of partici-
pants from focusing on only the suggested potential
barriers. Finally, we did not systematically collect in-
formation around participant gender and were there-
fore unable to analyse whether there were differences
between male and female patients.
Implications for future medication trial design
When designing clinical trials for FXS, researchers
should bear in mind the factors identified as barriers
to participation in this study as well as the potential
strategies for overcoming them. Such strategies
should include the following:
1 Providing more information in accessible and
easy‐to‐understand formats, including as much
safety data as, is possible.
2 Holding information evenings where families can
meet the research team and ask questions.
3 Providing materials to help people with FXS fa-
miliarise themselves with the research environ-
ment and team in advance.
4 Providing medication in different preparations
5 When blood tests are required, provide informa-
tion to help prepare individuals with FXS for this.
If possible, design a desensitisation programme to
facilitate blood testing.
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6 Consider the number of visits needed for the
study and the travel and time that would be re-
quired, looking at whether it would be feasible
to do a combination of local, remote and more
distant site visits if required.
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